Efsubaglutide Alfa received its first regulatory approval in China on January 24, 2025, from the National Medical Products Administration (NMPA).

Garadacimab is an innovative, fully human IgG4 monoclonal antibody specifically designed to target activated Factor XII (FXIIa).

Datopotamab Deruxtecan (Dato-DXd) is a Trop-2-targeting antibody-drug conjugate (ADC) developed jointly by Daiichi Sankyo and AstraZeneca.

Recaticimab, a monoclonal antibody developed by Hengrui Medicine, was approved by the National Medical Products Administration (NMPA) in China on January 8, 2025.

In this article, we present a comprehensive overview of drugs that received their first global approvals in January 2025, along with an analysis of these therapies.

Johnson & Johnson announced its acquisition of Intra-Cellular Therapies, a biopharmaceutical company focused on central nervous system (CNS) disorders.

In 2024, the range of diseases treated by globally approved new drugs was diverse, with cancer and rare diseases leading in the total number of new drug approvals.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have garnered significant attention for their dual effects in glucose control and weight reduction.

The siRNA therapeutics market is expected to grow substantially from $12.7 billion in 2022 to $39.2 billion by 2029.

In an era characterized by information overload, effectively managing and utilizing vast amounts of biomedical data has become another pressing issue.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has announced that it has administered doses to the first participants in a Phase 1/2a clinical trial for ARO-INHBE.

In recent years, a molecular target known as Claudin18.2 has emerged as a prominent target in the treatment of gastric cancer, pancreatic cancer, and various other solid tumors.